Circadian rhythms in rheumatology - a glucocorticoid perspective

Arthritis Research and Therapy

Volumn 16, Issue , 2014, Pages

  Spies, Cornelia M ^a   Straub, Rainer H ^b   Cutolo, Maurizio ^c   Buttgereit, Frank ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; BETAMETHASONE; C REACTIVE PROTEIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; DUTIMELAN; GLUCOCORTICOID; HYDROCORTISONE; INTERLEUKIN 6; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISONE; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA; IL6 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ANKYLOSING SPONDYLITIS; ASTHMA; BEDTIME DOSAGE; CHRONIC INFLAMMATION; CIRCADIAN RHYTHM; CONTROLLED RELEASE FORMULATION; CORTICOTROPIN TEST; CUSHING SYNDROME; CYTOKINE RELEASE; DOSAGE SCHEDULE COMPARISON; DRUG CHRONOTHERAPY; EVENING DOSAGE; GIANT CELL ARTERITIS; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOW DRUG DOSE; MORNING DOSAGE; MORNING STIFFNESS; NEGATIVE FEEDBACK; REVIEW; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SWELLING; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CHRONOPHARMACOLOGY; DRUG EFFECTS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFLAMMATION; LIVER; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION (PROCESS);

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADRENAL INSUFFICIENCY; ARTHRITIS, RHEUMATOID; CIRCADIAN RHYTHM; CORTICOTROPIN-RELEASING HORMONE; DRUG CHRONOTHERAPY; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFLAMMATION; INTERLEUKIN-6; LIVER; MULTICENTER STUDIES AS TOPIC; PITUITARY-ADRENAL SYSTEM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84978849117     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4687     Document Type: Review

References (49)

1. Straub RH, Cutolo M: Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 2007, 56: 399-408. 10.1002/art.22368.
2. Spies CM, Cutolo M, Straub RH, Burmester GR, Buttgereit F: More night than day - circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis. J Rheumatol. 2010, 37: 894-899. 10.3899/jrheum.091283.
3. Sierakowski S, Cutolo M: Morning symptoms in rheumatoid arthritis: a defining characteristic and marker of active disease. Scand J Rheumatol Suppl. 2011, 125: 1-5.
4. Straub RH, Bijlsma JW, Masi A, Cutolo M: Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases - the 10-year update. Semin Arthritis Rheum. 2013, 43: 392-404. 10.1016/j.semarthrit.2013.04.008.
5. Cutolo M: Chronobiology and the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2012, 24: 312-318. 10.1097/BOR.0b013e3283521c78.
6. Cutolo M: Rheumatoid arthritis: circadian and circannual rhythms in RA. Nat Rev Rheumatol. 2011, 7: 500-502. 10.1038/nrrheum.2011.115.
7. Cutolo M, Straub RH, Bijlsma JW: Neuroendocrine-immune interactions in synovitis. Nat Clin Pract Rheumatol. 2007, 3: 627-634. 10.1038/ncprheum0601.
8. Straub RH, Gluck T, Cutolo M, Georgi J, Helmke K, Scholmerich J, Vaith P, Lang B: The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica. Rheumatology. 2000, 39: 624-631. 10.1093/rheumatology/39.6.624.
9. Cutolo M, Foppiani L, Minuto F: Hypothalamic-pituitary-adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica. J Endocrinol Invest. 2002, 25: 19-23. 10.1007/BF03345073.
10. Caporali R, Cimmino MA, Montecucco C, Cutolo M: Glucocorticoid treatment of polymyalgia rheumatica. Clin Exp Rheumatol. 2011, 29: S143-S147.
11. Bollinger T, Bollinger A, Naujoks J, Lange T, Solbach W: The influence of regulatory T cells and diurnal hormone rhythms on T helper cell activity. Immunology. 2010, 131: 488-500. 10.1111/j.1365-2567.2010.03320.x.
12. Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS, Gold PW, Chrousos GP, Wilder RL: Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab. 1997, 82: 1279-1283. 10.1210/jcem.82.4.3852.
13. Straub RH, Paimela L, Peltomaa R, Scholmerich J, Leirisalo-Repo M: Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum. 2002, 46: 654-662. 10.1002/art.10177.
14. Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall G, Febbraio MA, Pedersen BK: Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol. 2003, 548: 631-638. 10.1113/jphysiol.2002.032938.
15. Tsigos C, Papanicolaou DA, Defensor R, Mitsiadis CS, Kyrou I, Chrousos GP: Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997, 66: 54-62. 10.1159/000127219.
16. Mastorakos G, Chrousos GP, Weber JS: Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993, 77: 1690-1694.
17. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014, 73: 492-509.
18. Buttgereit F: Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis?. Ann Rheum Dis. 2011, 70: 1881-1883. 10.1136/annrheumdis-2011-200388.
19. Narvaez J, Bernad B, Diaz Torne C, Momplet JV, Montpel JZ, Nolla JM, Valverde-Garcia J: Low serum levels of DHEAS in untreated polymyalgia rheumatica/giant cell arteritis. J Rheumatol. 2006, 33: 1293-1298.
20. Edwards C: Sixty years after Hench - corticosteroids and chronic inflammatory disease. J Clin Endocrinol Metab. 2012, 97: 1443-1451. 10.1210/jc.2011-2879.
21. Charmandari E, Nicolaides NC, Chrousos GP: Adrenal insufficiency. Lancet. 2014, 383: 2152-2167. 10.1016/S0140-6736(13)61684-0.
22. Kaiser H, Kley HK: Cortisontherapie. 2002, Stuttgart: Thieme Georg Verlag
23. Harbuz MS, Korendowych E, Jessop DS, Crown AL, Lipdfan SL, Kirwan JR: Hypothalamo-pituitary-adrenal axis dysregulation in patients with rheumatoid arthritis after the dexamethasone/corticotrophin releasing factor test. J Endocrinol. 2003, 178: 55-60. 10.1677/joe.0.1780055.
24. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA: Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000, 355: 542-545. 10.1016/S0140-6736(99)06290-X.
25. Klinefelter HF, Winkenwerder WL, Bledsoe T: Single daily dose prednisone therapy. JAMA. 1979, 241: 2721-2723. 10.1001/jama.1979.03290510029021.
26. Kirwan JR, Hickey SH, Hallgren R, Mielants H, Bjorck E, Persson T, Wollheim FA: The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. Arthritis Rheum. 2006, 54: 1415-1421. 10.1002/art.21747.
27. Jasani MK, Diver MJ, Bell AM, Dalakos TG, Buchanan WW: Some clinical observations on the diurnal rhythm of plasma cortisol (11-OHCS) in patients with rheumatoid arthritis treated with oral corticosteroid drugs. Curr Med Res Opin. 1974, 2: 373-386. 10.1185/03007997409112653.
28. Grant SD, Forsham PH, DiRaimondo VC: Suppression of 17-hydroxycorticosteroids in plasma and urine by single and divided doses of triamcinolone. N Engl J Med. 1965, 273: 1115-1118. 10.1056/NEJM196511182732101.
29. Haus E, Sackett-Lundeen L, Smolensky MH: Rheumatoid arthritis: circadian rhythms in disease activity, signs and symptoms, and rationale for chronotherapy with corticosteroids and other medications. Bull NYU Hosp Jt Dis. 2012, 70 (Suppl 1): 3-10.
30. Angeli A: Circadian ACTH-adrenal rhythm in man. Chronobiologia. 1974, 1 (Suppl 1): 253-270.
31. Nichols T, Nugent CA, Tyler FH: Diurnal variation in suppression of adrenal function by glucocorticoids. J Clin Endocrinol Metab. 1965, 25: 343-349. 10.1210/jcem-25-3-343.
32. Di Raimondo VC, Forsham PH: Some clinical implications of the spontaneous diurnal variation in adrenal cortical secretory activity. Am J Med. 1956, 21: 321-323. 10.1016/0002-9343(56)90033-X.
33. Di Raimondo VC, Forsham PH: Pharmacophysiologic principles in the use of corticoids and adrenocorticotropin. Metabolism. 1958, 7: 5-24.
34. Deandrade JR, McCormick JN, Hill AG: Small doses of prednisolone in the management of rheumatoid arthritis. Ann Rheum Dis. 1964, 23: 158-162. 10.1136/ard.23.2.158.
35. Smolensky MH, Peppas NA: Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev. 2007, 59: 828-851. 10.1016/j.addr.2007.07.001.
36. Myles AB, Schiller LF, Glass D, Daly JR: Single daily dose corticosteroid treatment. Ann Rheum Dis. 1976, 35: 73-76. 10.1136/ard.35.1.73.
37. De AJ: Pituitary-adrenocortical reserve during corticosteroid therapy: a report on the methopyrapone test in ten patients taking long-continued small doses. J Clin Endocrinol Metab. 1964, 24: 261-262. 10.1210/jcem-24-3-261.
38. Reinberg A, Guillet P, Gervais P, Ghata J, Vignaud D, Abulker C: One month chronocorticotherapy (Dutimelan 8 15 mite). Control of the asthmatic condition without adrenal suppression and circadian rhythm alteration. Chronobiologia. 1977, 4: 295-312.
39. McAllister WA, Mitchell DM, Collins JV: Prednisolone pharmacokinetics compared between night and day in asthmatic and normal subjects. Br J Clin Pharmacol. 1981, 11: 303-304. 10.1111/j.1365-2125.1981.tb00538.x.
40. Masi AT, Chrousos GP: Dilemmas of low dosage glucocorticoid treatment in rheumatoid arthritis: considerations of timing. Ann Rheum Dis. 1997, 56: 1-4. 10.1136/ard.56.1.1.
41. Arvidson NG, Gudbjornsson B, Larsson A, Hallgren R: The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis. 1997, 56: 27-31. 10.1136/ard.56.1.27.
42. De Silva M, Binder A, Hazleman BL: The timing of prednisolone dosage and its effect on morning stiffness in rheumatoid arthritis. Ann Rheum Dis. 1984, 43: 790-793. 10.1136/ard.43.6.790.
43. Owlia MB, Mehrpoor G, Modares Mosadegh M: Bedtime single-dose prednisolone in clinically stable rheumatoid arthritis patients. ISRN Pharmacol. 2012, 2012: 637204-
44. Karatay S, Senel K, Ugur M, Yildirim K: The timing of low dose glucocorticoid therapy in treatment of rheumatoid arthritis. Pain Clinic. 2002, 13: 305-312. 10.1163/15685690260138910.
45. Kowanko IC, Pownall R, Knapp MS, Swannell AJ, Mahoney PG: Circadian variations in the signs and symptoms of rheumatoid arthritis and in the therapeutic effectiveness of flurbiprofen at different times of day. Br J Clin Pharmacol. 1981, 11: 477-484. 10.1111/j.1365-2125.1981.tb01153.x.
46. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R: Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008, 371: 205-214. 10.1016/S0140-6736(08)60132-4.
47. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R: Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis. 2010, 69: 1275-1280. 10.1136/ard.2009.126888.
48. Alten R, Doring G, Cutolo M, Gromnica-Ihle E, Witte S, Straub R, Buttgereit F: Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J Rheumatol. 2010, 37: 2025-2031. 10.3899/jrheum.100051.
49. Clarke L, Jessop DS, Hunt LP, Straub RH, Perry MG, Kirwan J: Alleviation of morning joint stiffness by low-dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisol. Int J Clin Rheumatol. 2011, 6: 241-249. 10.2217/ijr.11.12.